Fungal infections in neutropenic cancer patients

Journal of the College of Physicians and Surgeons Pakistan

Volumn 13, Issue 11, 2003, Pages 669-673

  Parvez, Tariq ^a  

^a KING FAHAD HOSPITAL   (Saudi Arabia)

Author keywords

Fungal infections; Neutropenia; Opportunistic infection

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; CYCLOSPORIN; ECHINOCANDIN B DERIVATIVE; FLUCONAZOLE; FLUCYTOSINE; GRANULOCYTE COLONY STIMULATING FACTOR; ITRACONAZOLE; MICAFUNGIN; NYSTATIN; POSACONAZOLE; RAVUCONAZOLE; TACROLIMUS; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; ASPERGILLOSIS; ASPERGILLUS; CANCER PATIENT; CANDIDA; CANDIDIASIS; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG APPROVAL; DRUG CHOICE; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FUNGUS CULTURE; HUMAN; LIVER DYSFUNCTION; MYCOSIS; NEPHROTOXICITY; NEUTROPENIA; OPPORTUNISTIC INFECTION; REVIEW;

ANTIFUNGAL AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; FOLLOW-UP STUDIES; FUNGEMIA; HUMANS; IMMUNOCOMPROMISED HOST; MALE; NEOPLASMS; NEUTROPENIA; OPPORTUNISTIC INFECTIONS; PRIMARY PREVENTION; RISK ASSESSMENT; SURVIVAL ANALYSIS;

EID: 0346338257     PISSN: 1022386X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Groll AH, Shah PM, Mentzel C. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 1996; 33: 23-32.
2. Viscoli C, Girmenia C, Marinus A. Candidemia in cancer patients: a prospective, multicentre surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 1999; 28: 1071-9.
3. Groll AH, Walsh TJ. Uncommon opportunistic fungi: new nosocomial threats. Clin Microbiol Infect 2001; 7 (suppl 2): 8-24.
4. Groll AH, Piscitelli SC, Walsh TJ. Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv Pharmacol 1998; 44: 343-500.
5. Chiou CC, Groll AH, Walsh TJ. New drugs and novel targets for treatment of invasive fungal infections in patients with cancer. Oncologist 2000; 5: 120-35.
6. Rex JR, Walsh TJ, Nettleman M. Need for alternative trial designs and evaluation strategies for therapeutic studies of invasive mycoses. Clin Infect Dis 2001; 35: 95-106.
7. Centers for Disease Control and Prevention. Infections Diseases Society of America; American Society of Blood and Marrow Transplantation. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR Recom Rep 2000; 49: 1-125, CE-1-7.
8. Walsh TJ, Dixon DM. Nosocomial aspergillosis: environmental microbiology, hospital epidemiology, diagnosis and treatment. Eur J Epidemiol 1989; 5: 131-42.
9. Slavin MA, Osborne B, Adams R. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation: a prospective, randomized, double-blind study. J Infect Dis 1995; 171: 1545-52.
10. Marr KA, Seidel K, Slavin MA. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 2000; 96: 2055-61.
11. Kanda Y, Yamamoto R, Chizuka A, Hemaki T, Surugo M, Arai C, et al. Prophylactic action of oral fluconazole against fungal infection in neutropenic patients. A meta-analysis of 16 randomized, controlled trials. Cancer 2000; 89: 1611-25.
12. Bow EJ, Laverdiere M, Lussier N, Rotstein C, Cheang MS, Ioannou S. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials. Cancer 2002; 94: 3230-46.
13. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandar T, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clini Infecti Dis 2002; 34: 730-51.
14. Jarque I, Saavedra S, Martin G, Peman J, Parez Belles C, Sanz MA. Delay of onset of candidemia and emergence of Candida krusei fungemia in hematologic patients receiving prophylactic fluconazole. Haematologica 2000; 85: 441-3.
15. Marr KA, Seidel K, White TC, Bowden RA. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 2000; 181: 309-16.
16. Lortholary O, Dupont B. Antifungal prophylaxis during neutropenia and immunodeficiency. Clin Microbiol Rev 1997; 10: 477-504.
17. Empiric antifungal therapy in febrile granulocytopenic patients. EORTC International Antimicrobial Therapy Cooperative Group. Am J Med 1989; 86: 668-72.
18. Walsh TJ, Finberg RW, Arndt C. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 1999; 340: 764-71.
19. Boogaerts M, Winston DJ, Bow EJ. Intravenous and oral itraconazole versus intravenous amphotericin B as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. Ann Intern Med 2001; 135: 412-22.
20. Winston DJ, Hathorn JW, Schuster MG. A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. Am J Med 2000; 108: 282-9.
21. Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Peterson F, Raffalli J, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 346: 225-34.
22. Groll AH, Just-Nuebling G, Kurz M. Fluconazole versus nystatin in the prevention of Zandida infections in children and adolescents undergoing remission induction or consolidation chemotherapy for cancer. J Antimicrob Chemother 1997; 40: 855-62.
23. Semelka RC, Shoenut JP, Greenberg HM, Bow EJ. Detection of acute and treated lesions of hepatosplenic candidiasis: comparison of dynamic contrast-enhanced CT and MR imaging. J Magn Reson Imaging 1992; 2: 341-5.
24. Anaissie EJ, Darouiche RO, Abi-Said D. Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis 1996; 23: 964-72.
25. Lecciones JA, Lee JW, Navarro EE. Vascular catheter-associated fungemia in patients with cancer: analysis of 155 episodes. Clin Infect Dis 1992; 14: 875-83.
26. Noskin GA, Pietrelli L, Coffey G. Amphotericin B colloidal dispersion for treatment of candidemia in immunocompromised patients. Clin Infect Dis 1998; 26: 461-7.
27. Mora-Duarte J, Betts R, Rotstein C, Colombo AI, Thompson-Moya L, Smietana J, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347: 2020-9.
28. Rex JH, Walsh TJ, Sobel JD, Filler SG, Pappas PG, Dismukes WE, et al. Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Clin Infect Dis 2000; 30: 662-78.
29. Pannuti C, Gingrich R, Pfaller MA. Nosocomial pneumonia in patients having bone marrow transplant. Attributable mortality and risk factors. Cancer 1992; 69: 2653-62.
30. Sutton DA, Sanche SE, Revankar SG. In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole. J Clin Microbiol 1999; 37: 2343-5.
31. Caillot D, Casasnovas O, Bernard A. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomography scan and surgery. J Clin Oncol 1997; 15: 139-47.
32. Yeghen T, Kibbler CC, Prentice HG. Management of invasive pulmonary aspergillosis in hematology patients: a review of 87 consecutive cases at a single institution. Clin Infect Dis 2000; 31: 859-68.
33. Herbrecht R, Letscher-Bru V, Oprea C, Lioure B, Waller J, Campos F, et al. Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J Clin Oncol 2000; 20: 1898-906.
34. Bowden R, Chandrasekar P, White MH, Lix, Pietrelli L, Gurwith M, et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2002; 35: 359-66.
35. White MH, Anaissie EJ, Kusne S. Amphotericin B colloidal dispersion vs amphotericin B as therapy for invasive aspergillosis. Clin Infect Dis 1997; 24: 635-42.
36. Hiemenz JW, Walsh TJ. Lipid formulations of amphotericin B: recent progress and future directions. Clin Infect Dis 1996; 22 (suppl 2): 133-44.
37. Herbrecht R, Denning DW, Patterson TF. Open, randomized comparison of voriconazole (VRC) and amphotericin B (AmB) followed by other licensed antifungal therapy (OLAT) for primary therapy of invasive aspergillosis (IA). Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001; September 22-25: Chicago (Abstract J-680).
38. Caillot D, Bassaris H, Seifert WF. Efficacy, safety, and pharmacokinetics of intravenous followed by oral itraconazole in patients with invasive pulmonary aspergillosis. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999; September 26-29, San Francisco (Abstract 1646).
39. Maertens J, Raad I, Sable CA. Multicenter, non-comparative study to evaluate safety and efficacy of caspofungin in adults with invasive aspergillosis refractory or intolerant to amphotericin B, amphotericin B lipid formulations, or azoles. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000; September 17-20, Toronto (Abstract 1103).
40. Giglione C, Meinnel T. The situation on antimicrobial agents and chemotherapy in 2002: Highlights of the 42nd ICAAC. Expert Opin Ther Targets 2002; 6: 691-7.
41. Denning DW. Invasive aspergillosis. Clin Infect Dis 1998; 26: 781-805.
42. Wong K, Waters CM, Walesby RK. Surgical management of invasive pulmonary aspergillosis in immunocompromised patients. Eur J Cardiothorac Surg 1992; 6: 138-42.
43. Offner F, Cordonnier C, Ljungman P. Impact of previous aspergillosis on the outcome of bone marrow transplantation. Clin Infect Dis 1998; 26:1098-103.
44. Perfect JR, Schell WA. The new fungal opportunists are coming. Clin Infect Dis 1996; 22 (Suppl 2): S112-8.
45. Perfect JR, Marr KA, Walsh TJ, Greenberg RN, Dupont B, dela Torre-Cisneros J, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003; 36: 1122-31.
46. Bodey GP, Mardani M, Hanna HA, Boktour M, Abbas J, Girgawy E, et al. The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. Am J Med 2002; 112: 380-5.
47. Kohno S, Masaoka T, Yamaguchi H. A multicentre, open-label clinical study of FK463 in patients with deep mycoses in Japan. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001; September 22-25, Chicago (Abstract J-834).
48. Manavathu EK, Cutright JL, Loebenberg D, Chandrasekar PH. A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592). J Antimicrob Chemother 2000; 46: 229-34.
49. Aliff TB, Maslak PG, Jurcic JG, Heaney ML, Cathcart KN, Sepkowitz KA, et al. Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin. Cancer 2003; 97: 1025-32.
50. Rex JH, Pappas PG, Karchmer AW, Sobel J, Edwards JE, Hadley S, et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in no-nneutropenic subjects. Clin Infect Dis 2003; 36: 1221-8.
51. Dignani MC, Anaissie EJ, Hester JP. Treatment of neutropenia-related fungal infections with granulocyte colony-stimulating factor-elicited white blood cell transfusions: a pilot study. Leukemia 1997; 11: 1621-30.